Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18317231 | 0.84 | ALDH1A1 (0.42) | CYP2A6ALDH1A1CYP1A2TSHRHPGD | |
| SCHEMBL18317762 | 0.84 | CYP1A2 (0.48) | CYP2A6ALDH1A1CYP1A2TSHRHPGD | |
| SCHEMBL466417 | 0.83 | CYP2A6 (0.54) | CYP2A6ALDH1A1CYP1A2TSHRHPGD | |
| SCHEMBL2701310 | 0.79 | CYP1A2 (0.49) | CYP2A6ALDH1A1CYP1A2TSHRHPGD | |
| SCHEMBL2701259 | 0.79 | CYP1A2 (0.49) | CYP2A6ALDH1A1CYP1A2TSHRHPGD | |
| SCHEMBL6274844 | 0.77 | ALDH1A1 (0.33) | ALDH1A1CYP1A2TSHRHPGDHSD17B10 | |
| SCHEMBL384025 | 0.76 | CYP1A2 (0.56) | ALDH1A1CYP1A2TSHRHPGDHSD17B10 | |
| SCHEMBL643920 | 0.74 | CYP2A6 (0.54) | CYP2A6CYP1A2TSHRCA9HSD17B1 | |
| SCHEMBL146326 | 0.74 | BACE1 (0.34) | CA9 | |
| SCHEMBL7834664 | 0.74 | NOS1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778639-B1 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RES INC (US) | 2015-09-02 | — | — | EP | claimed |
| US-9085531-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-07-21 | — | — | US | claimed |
| US-20140243524-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-08-28 | — | — | US | claimed |
| US-8741901-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-06-03 | — | — | US | claimed |
| US-20130005965-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-03 | — | — | US | claimed |
| US-8236796-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-08-07 | — | — | US | claimed |
| US-8227486-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-24 | — | — | US | claimed |
| CN-1645254-B | Chemical amplification type positive resist composition | SUMITOMO CHEMICAL CO | 2010-05-12 | — | — | CN | claimed |
| US-20090253906-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2009-10-08 | — | — | US | claimed |
| US-7541357-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | AMR TECHNOLOGY, INC. (US) | 2009-06-02 | — | — | US | claimed |
| US-20090048443-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2009-02-19 | — | — | US | claimed |
| EP-1778639-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR Technology, Inc. (US) | 2007-05-02 | — | — | EP | claimed |
| US-20060052378-A1 | Psychological disorders; analgesics; eating disorders; drug abuse; 4-(8-chloro-naphthalen-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-(6-methoxy-pyrazin-2yl)-2-methyl-4-(naphthalene-2-yl)-1,2,3,4-tetrahydroisoquinoline; treating amide intermediates with sodium borohydride | CURIA GLOBAL, INC. | 2006-03-09 | — | — | US | claimed |
| WO-2006020049-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| EP-3908566-B1 | PREPARATION OF 5-ARYL PENTANOLS | BASF SE (DE) | 2023-07-26 | — | — | EP | disclosed |
| US-11581567-B2 | Lithium ion battery and electrolyte thereof | CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED (CN) | 2023-02-14 | — | — | US | disclosed |
| US-11365168-B2 | Preparation of 5-aryl-pentanols | BASF SE (DE) | 2022-06-21 | — | — | US | disclosed |
| US-3957892-A | A CONJUGATED DIENE AND A PHENOL | ETHYL CORPORATION (US) | 1976-05-18 | — | — | US | disclosed |
| US-3950145-A | ANTIKNOCK | ETHYL CORPORATION (US) | 1976-04-13 | — | — | US | disclosed |
| US-3948618-A | GASOLINE; A CYCLOPENTADIENYL MANGANESE TRICARBONYL ANTIKNOCK AGENT | ETHYL CORPORATION (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11581567-B2 | Lithium ion battery and electrolyte thereof | PLCB1, PLCB3, LAGE3 | CYP2A6 4413/4885ALDH1A1 4709/4885CYP1A2 4570/4885 |
| US-11365168-B2 | Preparation of 5-aryl-pentanols | HPD, CYP3A5, HTR3C | CYP2A6 69/4885ALDH1A1 127/4885CYP1A2 18/4885 |
| US-20060052378-A1 | Psychological disorders; analgesics; eating disorders; drug abuse; 4-(8-chloro-naphthalen-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-(6-methoxy-pyrazin-2yl)-2-methyl-4-(naphthalene-2-yl)-1,2,3,4-tetrahydroisoquinoline; treating amide intermediates with sodium borohydride | OPRK1, OPRL1, OPRD1 | CYP2A6 536/4885ALDH1A1 777/4885CYP1A2 196/4885 |
| US-20090253906-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | DRD4, SLC6A4, HTR4 | CYP2A6 742/4885ALDH1A1 954/4885CYP1A2 146/4885 |
| US-20130005965-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | DRD4, SLC6A4, HTR4 | CYP2A6 742/4885ALDH1A1 954/4885CYP1A2 146/4885 |
| US-20090048443-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | DRD4, SLC6A2, SLC6A3 | CYP2A6 740/4885ALDH1A1 1013/4885CYP1A2 142/4885 |
| US-20140243524-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | DRD4, SLC6A4, HTR4 | CYP2A6 742/4885ALDH1A1 954/4885CYP1A2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.